Adicet Bio (ACET) vs TherapeuticsMD (TXMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TherapeuticsMD (TXMD) has outperformed Adicet Bio (ACET) over the past year, losing 3.9% versus a loss of 77.8%. Over five years, TXMD leads with a -94.1% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $19.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | TXMD |
|---|---|---|
| Share price | $2.14 | $1.71 |
| Market cap | $20.03M | $19.79M |
| 1-day change | -13.01% | -5.52% |
| YTD return | -74.58% | +4.91% |
| 1-year return | -77.78% | -3.93% |
| 5-year return | -98.58% | -94.10% |
| P/E ratio (TTM) | — | 171.00 |
| Forward P/E | — | 4.89 |
| EPS (TTM) | $-7.53 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.02M |
| Revenue growth (YoY) | — | +71.61% |
| Net income (latest FY) | $-116.80M | $-569.00K |
| Operating margin | — | -145.27% |
| Net margin | — | -18.83% |
| 52-week high | $11.15 | $2.95 |
| 52-week low | $2.12 | $1.43 |
| Distance from 52-week high | -80.81% | -42.03% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1527.57% | — |
| Average volume | 271.05K | 24.50K |
| Shares outstanding | 9.36M | 11.57M |
| Employees | 102 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXMD has outperformed ACET by 73.8 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About TherapeuticsMD
TXMD stock →TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
ACET vs TXMD FAQ
Which is bigger, Adicet Bio or TherapeuticsMD?
Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $19.79M for TherapeuticsMD (TXMD).
Which stock has performed better over the past year, ACET or TXMD?
TXMD returned -3.93% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and TherapeuticsMD in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.